Epigenetics: an emerging technology in the diagnosis and treatment of cancer (Q36555927)

14 August 2017

1 reference

title

Epigenetics: an emerging technology in the diagnosis and treatment of cancer (English)

1 reference

14 August 2017

1 reference

Justin Stebbing

1

1 reference

14 August 2017

Mark Bower

2

1 reference

14 August 2017

Nelofer Syed

3

1 reference

14 August 2017

Paul Smith

4

1 reference

14 August 2017

Veronica Yu

5

1 reference

14 August 2017

Tim Crook

6

1 reference

14 August 2017

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

747-757

1 reference

14 August 2017

5

1 reference

Mutator phenotypes in human colorectal carcinoma cell lines

14 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Restriction landmark genomic scanning for DNA methylation in cancer: past, present, and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Epigenomics: mapping the methylome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Chfr defines a mitotic stress checkpoint that delays entry into metaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

DNA methylation and gene silencing in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Inhibitors of DNA methylation: beyond myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

DNA Methylation and Gene Function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

The silence of the genes: epigenetic disturbances in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Epigenetic drugs: a longstanding story

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Differential DNA methylation of gene promoters in small B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Methylation profiling in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.747

21 January 2018

Identifiers

DOI

10.2217/14622416.7.5.747

1 reference

14 August 2017

1 reference